Compare General Motors Company (GM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Twist Bioscience Corp — how do they compare? General Motors Company trades at $82.5 (market cap $71.06B), while Twist Bioscience Corp trades at $157 (market cap $10.32B). The key difference: General Motors Company is far larger — about 6.9× Twist Bioscience Corp's market cap, and General Motors Company pays a 0.89% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Twist Bioscience Corp for 27 Days on average.
| GM | TWST | |
|---|---|---|
Market Cap | $71.06B | $10.32B |
Volume | 6,269,264 | 5,894,998 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $205.00 |
52-Week Low | $55.35 | $25.45 |
Typical Hold Time | 83 Days | 27 Days |
Enterprise Value | $174.04B | $10.24B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $80.99, down 1.24% on the day, amid a broader market downturn and weak Q3 2026 vehicle sales. The stock shows a bearish technical signal, with key support at $80. Fundamentally, GM's revenue dipped to $185.02B in 2025 with a thin net margin of 1.05%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights competitive pressure from Toyota and a 5.5% decline in Q3 U.S. sales, driven by EV softness.
GM faces headwinds from declining market share and high debt levels, but analyst consensus remains bullish with a $102.08 price target, implying significant upside. Investment appeal hinges on execution amid industry shifts, while risks include rising borrowing costs and intense competition. Cash flow stability offers some cushion, but profitability recovery is critical for sustained gains.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
